Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT01954147
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 100 participants
- Sponsor
- Diabetes Care Center of Nanjing Military Command
- Registry
-
NCT01954147
-
- Other papers using this trial's data
- [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus]
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01954147. Non-randomized; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- GLP-1
- Intervention (Biological)
- SC
- Intervention (Other)
- Standard Medical Treatment
- Lead sponsor
- Diabetes Care Center of Nanjing Military Command
Record details
- Record id
cardio:ct-nct01954147- Content hash
e9e24d6787d1cdb3b9e98501c51fe82489a2ffa2785fa33d7a55c489f7f8fec9